Suppression of breast cancer invasion and migration by indole-3- carbinol: Associated with up-regulation of BRCA1 and E-cadherin/catenin complexes

Journal of Molecular Medicine

Volumn 78, Issue 3, 2000, Pages 155-165

  Meng, Qinghui ^a   Qi, Mei ^a   Chen, Da Zhi ^a   Yuan, Renqi ^a   Goldberg, Itzhak D ^a   Rosen, Eliot M ^a   Auborn, Karen ^a   Fan, Saijun ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

BRCA1; E Cadherin catenin; Human breast cancer; Indole 3 carbinol; Invasion; Migration

Indexed keywords

3 INDOLEMETHANOL; BRCA1 PROTEIN; CATENIN; UVOMORULIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CONTROL; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE;

EID: 0034042381     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000088     Document Type: Article

References (51)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8-13
2. 2. Telang NT, Bradlow HL, Osborne MP (1992) Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention. J Cell Biochem 160:161-169
3. 3. Liu H, Wormke M, Safe SH, Bjeldanes LF (1994) Indolo [3,2-b]carbazole: a dietary-derived factor that exhibits both antiestrogenic and estrogenic activity. J Natl Cancer Inst 86: 1758-1765
4. 4. Wong GY, Bradlow L, Sepkovic D, Mehl S, Mailman J, Osborne MP (1997) Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem 28-29:111-116
5. 5. Chen I, Safe S, Bjeldanes L (1999) Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51:1069-1076
6. 6. Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, Firestone GL (1999) Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59:1244-1251
7. 7. Carughi A (1997) Antiproliferative effect of a blend of extracts from cruciferous vegetables on human breast cancer. FASEB J 11:A369
8. 8. Bradlow HL, Michnovicz J, Telang NT, Osborne MP (1991) Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12:1571-1574
9. 9. Michnovicz JJ, Bradlow HL (1991) Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 16:59-66
10. 10. Jellinck PH, Michnovicz JJ, Bradlow HL (1991) Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids 56:446-450
11. 11. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP (1994) Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 86:126-131
12. 12. Telang NT, Katdare M, Bradlow HL, Osborne MP, Fishman J (1997) Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 216:246-252
13. 13. Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldanes LF (1999) Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol 58:825-834
14. 14. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL, Auborn K (1999) Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 19:1673-1680
15. 15. Jin L, Qi M, Chen DZ, Anderson A, Yang GY, Arbeit JM, Auborn KJ (1999) Indole-3-Carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res 59:3991-3997
16. 16. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ (1987) A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38:137-147
17. 17. Goodman, SL, Vollmers HP and Birchmeier W (1985) Control of cell locomotion: perturbation with an antibody directed against specific glycoproteins. Cell 41:1029-1038
18. 18. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM (1998) BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16:3069-3082
19. 19. Rockwell S (1981) Effect of host age on the transplantation, growth, and radiation response of EMT6 tumors. Cancer Res 41:527-531
20. 20. Pierceall WE, Woodard AS, Morrow JS, Rimm D, Fearon ER (1995) Frequent alterations in E-cadherin and α- and β-catenin expression in human breast cancer cell lines. Oncogene 11: 1319-1326
21. 21. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL (1998) Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273:3838-3847
22. 22. Chen I, McDougal A, Wang F, Safe S (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19:1631-1639
23. 23. Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9:317-321
24. 24. Bracke ME, Van Roy FM, Mareel MM (1996) The E-cadherin/ catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 213:123-161
25. 25. Zschiesche W, Schonborn I, Behrens J, Herrenknecht K, Hartveit F, Lilleng P, Birchmeier W (1997) Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561-567
26. 26. Bukhokn IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL (1998) E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 185:262-266
27. 27. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ (1996) Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105:394-402
28. 28. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115
29. 29. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13:1919-1925
30. 30. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183:404-411
31. 31. Hunt NC, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M (1997) Loss of E-cadlierin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch 430:285-289
32. 32. Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, Doggett N, Johnson K, Wheelock M, Herman J, Baylin S, Pinkel D, Gray J (1998) Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res 58: 1972-1977
33. 33. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R, Lavaut MN, Allasia C (1998) Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 109: 431-838
34. 34. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Hofler H, Becker KF (1999) Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18:4301-4312
35. 35. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56:4063-4070
36. 36. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V (1994) Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 54:4607-4609
37. 37. Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ (1998) Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390
38. 38. Albini A, Graf J, Kitten GT, Kleinman HK, Martin GR, Veillette A, Lippman ME (1986) 17 beta-estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci USA 83:8182-8186
39. 39. Fujimoto J, Hori M, Ichigo S, Morishita S, Tamaya T (1996) Estrogen activates migration potential of endometrial cancer cells through basement membrane. Tumour Biol 17:48-57
40. 40. Shafie SM, Liotta LA (1980) Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett 11:81-87
41. 41. Osborne CK, Hobbs K, Clark GM (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590
42. 42. Bliss RD, Kirby JA, Browell DA, Lennard TW (1996) Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen. Eur J Surg Oncol 22:27-33
43. 43. Xing RH, Mazar A, Henkin J, Rabbani SA (1997) Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 57:3585-3593
44. 44. Couissi D, Dubois V, Remade C, Schonne E, Trouet A (1997) Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by17beta-estradiol, tamoxifen and ICI 182,780. Clin Exp Metastasis 15:349-360
45. 45. Tedone T, Correale M, Barbarossa G, Casavola V, Paradiso A, Reshkin SJ (1997) Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J 11:785-792
46. 46. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM (1999) BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284:1354-1356
47. 47. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
48. 48. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450
49. 49. Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, Coombes RC, Ali S (1998) An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 79:334-342
50. 50. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI (1999) BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84:258-262
51. 51. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX (1999) Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43